On October 20, 2025, scientists announced a significant advancement toward curing HIV, marking a pivotal moment in the ...

GSK raised its 2025 sales and earnings forecasts on Wednesday as its speciality HIV and cancer drugs posted double digit ...

Leaders in HIV research highlighted the critical role of that research has played in advancing HIV science over the past 40 years. In a commentary in Nature Medicine, they explained how U.S.-funded ...

Merck's two-drug HIV regimen doravirine/islatravir maintained viral suppression and matched Gilead's Biktarvy in Phase 3 ...

B/F/TAF shows lower ART switching rates and higher persistence among HIV patients, especially those with mental health or ...

More than 40 years after the first AIDS cases, new long-acting drugs and antibody-based therapies are reviving hopes that HIV ...

Shares in the company rose on Wednesday morning as a result, lifting to their highest level for more than a year.

Addressing the question of whether and how immune cells (macrophages) in the central nervous system (CNS) traffic out, ...

After abruptly pausing PEPFAR on Tuesday — the U.S.-led HIV/AIDS program created in 2003 and credited with saving 25 million lives globally — the Trump administration issued an ambiguous waiver for ...

Miguel, a 63-year-old Los Angeles teacher, recently marked the 38th anniversary of his diagnosis with HIV. The doctor had told him he would be dead in a couple of years. He lived fearful that each ...

In this Oct. 7, 2019, file photo, a pharmacist displays the HIV prevention drugs Descovy, left and Truvada, right, at a pharmacy in Sacramento, Calif. A proposed federal policy aims to protect older ...

The NIH funding will help address a "traditional barrier" to health care, says Elizabeth Evans, professor of community health ...